Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is a multicenter, open-label, postmarketing surveillance study. The substudy will collect information on BMD in adolescents and young adults with GHD or Turner syndrome who are completing GH treatment for statural indications.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 17 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
primary care clinic
Bone age of at least 15 years for girls or at least 16 years for boys within 6 months of obtaining the DXA scan
Previous enrollment in the NCGS core study, 85-036
Tanner Stage 4 or greater
Either spontaneous or induced puberty
Subjects who plan on terminating GH treatment for statural purposes for one or more of the following reasons: epiphyseal fusion, slowing growth rate indicates that near adult height has been reached, or satisfied with current height
Current therapy with a non Genentech GH product
Pregnancy (to avoid exposure to low levels of radiation from DXA scanners)
Endocrine System Diseases
Primary Ovarian Insufficiency
Bone Diseases, Developmental
Bone Diseases, Endocrine
Central Nervous System Diseases
Nervous System Diseases
Disorders of Sex Development
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Sex Chromosome Disorders
Genetic Diseases, Inborn